IMMUNITYBIO, INC. Proceeds from Stock Options Exercised
IMMUNITYBIO, INC. (IBRX) reported Proceeds from Stock Options Exercised of $971.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2026-05-07
- IMMUNITYBIO, INC. proceeds from stock options exercised for the quarter ending 2026-03-31 was $971.00K, a 341.36% increase year-over-year.
- IMMUNITYBIO, INC. proceeds from stock options exercised for the quarter ending 2025-03-31 was $220.00K.
- IMMUNITYBIO, INC. proceeds from stock options exercised for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- IMMUNITYBIO, INC. proceeds from stock options exercised for the quarter ending 2023-12-31 was $1.00K.
- IMMUNITYBIO, INC. proceeds from stock options exercised for fiscal 2023 was $294.00K, a 297.30% increase from fiscal 2022.
- IMMUNITYBIO, INC. proceeds from stock options exercised for fiscal 2022 was $74.00K, a 98.64% decline from fiscal 2021.
- IMMUNITYBIO, INC. proceeds from stock options exercised for fiscal 2021 was $5.46M, a 364.37% increase from fiscal 2020.
- IMMUNITYBIO, INC. proceeds from stock options exercised for fiscal 2020 was $1.18M, a 71.22% decline from fiscal 2019.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month | Proceeds from Stock Options Exercised 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | $971.00K 10-Q · filed 2026-05-07 | ||||
| 2025-03-31 | $220.00K 10-Q · filed 2026-05-07 | ||||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | $1.00K derived: sum of 2 quarters · filed 2024-05-09 | $33.00K derived: sum of 3 quarters · filed 2024-05-09 | $168.00K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2023-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $33.00K derived: sum of 2 quarters · filed 2024-03-19 | $168.00K derived: sum of 3 quarters · filed 2024-03-19 | $294.00K 10-K · filed 2024-03-19 | |
| 2023-09-30 | $32.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $167.00K derived: sum of 2 quarters · filed 2023-11-09 | $293.00K 10-Q · filed 2023-11-09 | $293.00K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2023-06-30 | $135.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $261.00K 10-Q · filed 2023-08-08 | $261.00K derived: sum of 3 quarters · filed 2024-05-09 | $261.00K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2023-03-31 | $126.00K 10-Q · filed 2024-05-09 | $126.00K derived: sum of 2 quarters · filed 2024-05-09 | $126.00K derived: sum of 3 quarters · filed 2024-05-09 | $126.00K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $0.00 derived: sum of 2 quarters · filed 2024-03-19 | $0.00 derived: sum of 3 quarters · filed 2024-03-19 | $74.00K 10-K · filed 2024-03-19 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $74.00K 10-Q · filed 2023-11-09 | $425.00K derived: sum of 4 quarters · filed 2024-03-19 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $74.00K 10-Q · filed 2023-08-08 | $425.00K derived: sum of 3 quarters · filed 2024-03-19 | $1.10M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2022-03-31 | $74.00K 10-Q · filed 2023-05-11 | $425.00K derived: sum of 2 quarters · filed 2024-03-19 | $1.10M derived: sum of 3 quarters · filed 2024-03-19 | $4.41M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2021-12-31 | $351.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $1.03M derived: sum of 2 quarters · filed 2024-03-19 | $4.34M derived: sum of 3 quarters · filed 2024-03-19 | $5.46M 10-K · filed 2024-03-19 | |
| 2021-09-30 | $678.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $3.99M derived: sum of 2 quarters · filed 2022-11-09 | $5.11M 10-Q · filed 2022-11-09 | $5.37M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | $3.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $4.43M 10-Q · filed 2022-08-08 | $4.69M derived: sum of 3 quarters · filed 2023-03-01 | $5.09M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | $1.12M 10-Q · filed 2022-05-10 | $1.38M derived: sum of 2 quarters · filed 2023-03-01 | $1.78M derived: sum of 3 quarters · filed 2023-03-01 | $2.38M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-12-31 | $259.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $659.00K derived: sum of 2 quarters · filed 2023-03-01 | $1.26M derived: sum of 3 quarters · filed 2023-03-01 | $1.18M 10-K · filed 2023-03-01 | |
| 2020-09-30 | $400.00K 10-Q · filed 2020-11-09 | $1.00M derived: sum of 2 quarters · filed 2020-11-09 | $917.00K 10-Q · filed 2021-11-12 | $1.02M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $600.00K 10-Q · filed 2020-08-07 | $564.00K 10-Q · filed 2021-08-12 | $616.00K derived: sum of 3 quarters · filed 2022-03-01 | $616.00K derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-14 | $16.00K derived: sum of 2 quarters · filed 2022-03-01 | $16.00K derived: sum of 3 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $16.00K derived: sum of 2 quarters · filed 2022-03-01 | $4.09M 10-K · filed 2022-03-01 | $4.07M 10-K · filed 2021-03-04 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $4.07M 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | $4.07M 10-Q · filed 2020-08-07 | ||||
| 2018-12-31 | $0.00 10-K · filed 2021-03-04 | ||||
| 2017-12-31 | $1.15M 10-K · filed 2018-03-12 | ||||
| 2016-12-31 | $1.37M 10-K · filed 2018-03-12 | ||||
| 2016-06-30 | $818.00K 10-Q · filed 2016-08-15 | ||||
| 2015-12-31 | $35.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $110.00K derived: sum of 2 quarters · filed 2018-03-12 | $878.00K 10-K · filed 2018-03-12 | ||
| 2015-09-30 | $75.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $843.00K 10-Q · filed 2015-11-12 | |||
| 2015-06-30 | $768.00K 10-Q · filed 2016-08-15 | ||||
| 2014-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $180.00K 10-K · filed 2017-03-15 | |||
| 2014-09-30 | $80.00K 10-Q · filed 2015-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |